Sami-Sabinsa Group Opens 2nd Continuous Extraction Facility to Meet Curcumin C3 Complex® Demand

Sabinsa’s parent company Sami Labs, which manufactures and markets phytonutrients and standardized herbal extracts, specialty fine chemicals, and organic intermediates used in the nutritional, pharmaceutical and food industries, inaugurated a second Continuous Extraction Plant on October 5, 2017, to meet demand for Curcumin C3 Complex^®.

This new facility will be exclusively used for curcumin extraction, increasing production of Curcumin C3 Complex to 25 tons from the previous capacity of 6 tons. The two Continuous Extraction units are spread across 5 acres in Dobaspet, Bangalore, India.

Seeking to avoid the seemingly ubiquitous artificial ingredients in the food and cosmetics industry, health conscious consumers have increased the demand for natural herbal extracts globally. That preference for natural, accompanied by a robust body of research, has fueled enormous growth in the curcumin extract market. According to a new research report by Frost & Sullivan, the global curcumin market is expected to reach more than $100 million by 2023, which is growing at a CAGR of 12.6% from 2017 to 2023. While the demand for curcumin in dietary supplements, pharmaceuticals, and cosmetics have experienced continuous growth, nutraceuticals make up more than 50% of the curcumin demand share, both by volume and revenue, and continue to grow faster than the other segments.

“Because of turmeric’s historic place in India’s traditional medical system Ayurveda, India dominates world turmeric production, with 80% taking place here," said Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group. “With our Curcumin C3 Complex the world leader in curcumin ingredients, expanding extraction capacity to ensure that we can continue to meet demand was the logical next step.”

About Sabinsa Corporation:

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 29 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher. For more information, visit www.sabinsa.com or  www.sabinsacosmetics.com

About Sami Labs Ltd.:

Founded by Dr. Muhammed Majeed, an internationally acclaimed scientist and entrepreneur in the area of “Alternative Medicine”, Sami Labs Limited is a research-oriented Indian multinational health science company, and a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, and probiotics. The Government of India honored Sami Labs Limited with the National Award for Quality Products (Basic Drugs) in the year 1994 and the Prestigious DSIR award in the year 2002. The company is endowed with independent research divisions including Natural drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulations R&D, all of which coordinate in a synergistic work model to create products meeting international standards.